Recipharm, a leading contract development and manufacturing organisation (CDMO) has announced the launch of its standalone serialisation service ahead of the introduction of the EU Falsified Medicines Directive (FMD).
The new service is designed to offer pharmaceutical companies access to Recipharm’s serialisation capabilities as a standalone service due to increasing concerns that many will not be ready for the February 2019 compliance deadline. Moving forward Recipharm will be able to add 2D codes, human readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.
”This new offering is the latest phase in our company-wide serialisation project which was launched in 2016 following a EUR 40 million investment,” commented Staffan Widengren, Director of Corporate Projects at Recipharm and Head of the Global Steering Committee for Recipharm’s serialisation programme.
Headquartered in Stockholm (Sweden), Recipharm has already delivered over 1.3 million serialised and aggregated packs to markets such as China, South Korea, Saudi Arabia and Turkey, and 0.5 million packs to the US, where serialisation regulations are currently in place.
Recipharm, a leading CDMO in the pharmaceutical industry, offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. The company manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies.